HealthcareServices

Personalized Cancer Treatment Market Outlook 2026–2030: Key Business Drivers and Trends

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the personalized cancer treatment market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Personalized Cancer Treatment Market expected to grow between 2026 and 2030?

The personalized cancer treatment market has expanded considerably over recent years. Projections indicate a rise from $200.98 billion in 2025 to $222.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.7%. Historically, this market’s expansion can be linked to aspects such as restricted access to genetic testing, dependency on traditional chemotherapy, insufficient understanding of personalized medicine’s advantages, a disjointed oncology healthcare infrastructure, and a scarcity of approvals for targeted therapies.

The personalized cancer treatment market is projected for swift expansion over the coming years, with its size expected to reach $332.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. This anticipated growth is driven by factors such as escalating investment in genomics research, the increasing adoption of liquid biopsy and biomarker testing, a rising demand for targeted therapies and immunotherapies, the integration of AI and big data in treatment planning, and the expansion of precision oncology clinical trials. Major trends foreseen during this forecast period include the growing embrace of AI-based genomic analytics for cancer treatment, the expanding implementation of precision medicine platforms, the greater utilization of biomarker-based diagnostic techniques, the deeper integration of digital health solutions in oncology, and the increased uptake of immersive technologies for patient monitoring and education.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19135&type=smp

Which Drivers Are Influencing Market Acceleration In The Personalized Cancer Treatment Market?

The increasing cancer prevalence is projected to propel the growth of the personalized cancer treatment market going forward. This rise in cancer is primarily attributed to longer life expectancy, which results in more people reaching an age where cancer is more common, and growing exposure to risk factors such as tobacco, alcohol, and obesity. Personalized cancer treatments offer targeted and effective therapies to manage various cancer types and stages; this expanding burden stimulates investment and innovation in precision medicine, aiming to improve patient outcomes through customized treatment plans. For instance, in February 2024, according to the World Health Organization, a Switzerland-based United Nations agency dedicated to global health and safety, the global cancer burden is anticipated to rise significantly, with an expected 77% increase in new cancer cases, reaching over 35 million by 2050 compared to 20 million in 2022. Consequently, increasing cancer prevalence is driving the growth of the personalized cancer treatment market.

What Leading Segments Are Studied In The Personalized Cancer Treatment Market?

The personalized cancer treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Immunotherapy, Hormone Therapy, Chemotherapy, Radiation Therapy, Other Treatment Type

2) By Diagnostic Techniques: Genomic Sequencing, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, Biomarker Testing, Other Diagnostic Techniques

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Cancer Types

4) By End-Users: Hospitals And Clinics, Research Institutes, Other End Users

Subsegments:

1) By Targeted Therapy: Monoclonal Antibodies, Small Molecule Inhibitors, Angiogenesis Inhibitors, Signal Transduction Inhibitors

2) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines, Monoclonal Antibodies For Immunotherapy

3) By Hormone Therapy: Anti-Estrogens, Aromatase Inhibitors, Progestins, LHRH Agonists

4) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Taxanes

5) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radioimmunotherapy, Stereotactic Radiosurgery (SRS)

6) By Other Treatment Types: Gene Therapy, Stem Cell Transplantation, Metabolic Therapy, Nanomedicine

Which Trends Are Expected To Influence The Personalized Cancer Treatment Market In The Upcoming Years?

Leading companies in the personalized cancer treatment market are concentrating on developing advanced solutions, such as artificial intelligence (AI)-powered multimodal immune profile algorithmic tests. These innovations aim to forecast patient responses to immunotherapy and enhance individualized treatment strategies. An AI-enabled multimodal immune profile algorithmic test analyzes various data types, including genomic, transcriptomic, and clinical biomarkers, to evaluate a patient’s immune profile and predict their reaction to immunotherapy, thereby assisting in patient stratification and guiding personalized cancer treatments. For instance, in July 2024, Tempus AI, Inc., a US-based health technology company, launched its AI-enabled multimodal immune profile algorithmic test (IPS), marking its first offering in the immunotherapy diagnostics space. This test, available for research use only (RUO), assesses a range of immunotherapy-related biomarkers to generate a score that helps predict patient response to immunotherapy, supporting personalized cancer treatment. Ultimately, these AI-driven, immunotherapy-focused diagnostics improve patient stratification and treatment selection in oncology.

Which Major Industry Participants Are Leading The Personalized Cancer Treatment Market Growth?

Major companies operating in the personalized cancer treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche, Merck & Co. Inc., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, BioNTech SE, Illumina Inc., Artera, Exact Sciences Corporation., Moffitt Cancer Center, Myriad Genetics, NeoGenomics Laboratories, Guardant Health, Caris Life Sciences, Tempus AI Inc., Foundation Medicine, Immatics, Fate Therapeutics, CureVac AG, TScan Therapeutics, CureMetrix, PDC*line Pharma

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-treatment-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Personalized Cancer Treatment Market?

North America was the largest region in the personalized cancer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Personalized Cancer Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19135&type=smp

Browse Through More Reports Similar to the Global Personalized Cancer Treatment Market 2026, By The Business Research Company

Cancer Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Cancer Supportive Care Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

Cancer Supportive Care Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795